# Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer

> **NCT00813163** · PHASE2 · COMPLETED · sponsor: **PharmaEngine** · enrollment: 41 (actual)

## Conditions studied

- Pancreatic Neoplasms

## Interventions

- **DRUG:** PEP02

## Key facts

- **NCT ID:** NCT00813163
- **Lead sponsor:** PharmaEngine
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2010-12
- **Final completion:** 2012-07
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2019-09-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00813163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00813163, "Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00813163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*